Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
| Form | Size | Price | $/mg | Stock | Updated |
|---|---|---|---|---|---|
| vial | 5mg | $39.99$29.99 | $6.00/mg | In stock | Jul 8 |
| vial | 10mg | $70.00$49.99 | $5.00/mg | In stock | Jul 8 |
Single-vial list prices — bulk or bundle orders may be lower. Verify at vendor before purchase.
| Lot / Report | Tested | Purity | Lab | Panels | Status | |
|---|---|---|---|---|---|---|
| EP-250519-DS10 | Jun 2025 | 99.9% | Janoshik Analytical | Heavy metals | Unverified | View |
The FDA PCAC advisory committee meets July 23–24, 2026 to review nominations and make recommendations on compounding eligibility — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. DSIP is on the proposed list. If the FDA subsequently issues a final rule, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Disclosed Labs does not provide medical or legal advice.
Does Eternal Peptides sell DSIP?
Yes — Eternal Peptides currently lists DSIP in 2 variants starting at $49.99 ($5.00/mg).
Is Eternal Peptides's DSIP third-party tested?
Yes — Disclosed Labs has indexed 1 Certificate of Analysis for Eternal Peptides's DSIP, with the most recent showing 99.9% purity. Eternal Peptides holds an overall trust grade of B (82/100) across all 30 COAs on file.
What is Eternal Peptides's trust grade for DSIP?
Eternal Peptides has an overall Disclosed Labs trust grade of B (82/100), computed from 30 COAs across all peptides. The most recent DSIP COA was issued by Janoshik Analytical.
Where is the cheapest DSIP?
As of the latest data, Peptide Supply Co. offers DSIP at $3.00/mg — compare with Eternal Peptides's listing at $5.00/mg. See the full DSIP price comparison.
Is DSIP legal to buy?
DSIP is among the peptides under FDA review for the Category 1 (503A) bulk-substances list — removed from Category 2 in April 2026 but not yet on a finalized Category 1 list. The FDA PCAC committee meets July 23–24, 2026 to make recommendations on which peptides may be compounded, and under what conditions — the PCAC is advisory only, and the FDA would issue any final rule on a separate, later timeline. If a final rule is ultimately issued, a valid prescription from a licensed prescriber may be required for compounding access; timing is uncertain. Current sales are for research purposes only. Disclosed Labs does not provide medical or legal advice.
Disclosed Labs